Phase II study of liposomal doxorubicin (Myocet®), docetaxel and trastuzumab combination as first line treatment of patients with her-2/neu positive locally advanced or metastatic breast cancer

被引：0
|
作者：
Amadori, D.
Gasparini, G.
Ardizzoni, A.
Comella, G.
Saracchini, S.
Barone, C.
Bordonaro, R.
Djazouli, K.
Barbalo, A.
机构：
[1] Ist Sci Romagnolo Studio & Lacura Tumori, Meldola, Forli Cesena, Italy
[2] Azienda Complesso Osped S Filippo Neri, Rome, Italy
[3] AO Univ Parma, Parma, Italy
[4] Fondaz G Pascale, Naples, Italy
[5] AO Santa Maria Angeli, Pordenone, Italy
[6] Policlin Univ A Gemelli, Rome, Italy
[7] Azienda Garibaldi, Catania, Italy
[8] Cephalon Europe, Paris, France
[9] Cephalon Srl, Rome, Italy
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：247S / 247S
页数：1
相关论文
共 50 条
  • [41] Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer
    Baselga, J.
    Manikhas, A.
    Cortes, J.
    Llombart, A.
    Roman, L.
    Semiglazov, V. F.
    Byakhov, M.
    Lokanatha, D.
    Forenza, S.
    Goldfarb, R. H.
    Matera, J.
    Azarnia, N.
    Hudis, C. A.
    Rozencweig, M.
    ANNALS OF ONCOLOGY, 2014, 25 (03) : 592 - 598
  • [42] Final results of a phase II study of liposomal cisplatin - vinorelbine combination as first-line treatment in HER2/neu negative metastatic breast cancer
    Farhat, F. S.
    Temraz, S.
    Kattan, J. G.
    Ibrahim, K.
    Bitar, N.
    Haddad, N.
    Hatoum, H.
    Shamseddine, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [43] Combination of trastuzumab, oxaliplatin, and docetaxel as first-line treatment in HER2-positive metastatic breast cancer patients: First-step results of a phase II trial (HOT trial)
    Amoroso, D.
    Donati, S.
    Valsuani, C.
    Puccetti, C.
    Rondini, M.
    Siclari, O.
    Tartarelli, G.
    Giannessi, P.
    Falcone, A.
    Camerini, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [44] An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer
    Cardoso, Fatima
    Canon, Jean-Luc
    Amadori, Dino
    Aldrighetti, Daniela
    Machiels, Jean-Pascal
    Bouko, Yasmina
    Verkh, Lev
    Usari, Tiziana
    Kern, Kenneth A.
    Giorgetti, Carla
    Dirix, Luc
    BREAST, 2012, 21 (06): : 716 - 723
  • [45] Phase II Study of Bevacizumab in Combination with Docetaxel and Capecitabine for the First-Line Treatment of Patients with Locally Recurrent or Metastatic Breast Cancer
    Musolino, A.
    Bisagni, G.
    De Matteis, A.
    Nuzzo, F.
    Ardizzoni, A.
    Crino, L.
    Gamucci, T.
    Passalacqua, R.
    Gnoni, R.
    Boni, C.
    CANCER RESEARCH, 2010, 70
  • [46] NON PEGYLATED LIPOSOMAL DOXORUBICIN (MYOCET) PLUS VINORELBINE VERSUS MYOCET PLUS CYCLOPHOSPHAMIDE AS FIRST LINE IN LOCALLY ADVANCED (LABC) OR METASTATIC BREAST CANCER (MBC): A RANDOMIZED MULTICENTER PHASE II TRIAL
    Lorusso, V
    Leo, S.
    Forcignano, R.
    Giotta, F.
    Bordonaro, R.
    Filippelli, G.
    Del Prete, S.
    Maiello, E.
    Gebbia, V
    Pisconti, S.
    Colucci, G.
    ANNALS OF ONCOLOGY, 2009, 20
  • [47] Non Pegylated Liposomal Doxorubicin (Myocet) Plus Vinorelbine Versus Myocet Plus Cyclophosphamide as First Line in Locally Advanced (Labc) or Metastatic Breast Cancer (Mbc): A Randomized Multicenter Phase II Trial
    Lorusso, V.
    Leo, S.
    Forcignano, R.
    Giotta, F.
    Bordonaro, R.
    Filippelli, G.
    Del Prete, S.
    Maiello, E.
    Gebbia, V.
    Pisconti, S.
    Colucci, G.
    ONCOLOGY, 2009, 77 : 151 - 151
  • [48] Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study
    Blackwell, Kimberly L.
    Zaman, Khalil
    Qin, Shukui
    Tkaczuk, Katherine H. R.
    Campone, Mario
    Hunt, Daniel
    Bryce, Richard
    Goldstein, Lori J.
    CLINICAL BREAST CANCER, 2019, 19 (02) : 97 - +
  • [49] Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients (pts) with HER2-positive metastatic breast cancer (MBC)
    Peacock, N. W.
    Infante, J. R.
    Yardley, D. A.
    Burris, H. A., III
    Greco, F. A.
    Farley, C.
    Webb, C.
    Spigel, D. R.
    Hainsworth, J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [50] Phase II Study of Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide plus /- Trastuzumab Followed by Docetaxel in Locally Advanced Breast Cancer (LABC)
    Tuxen, M. K.
    Cold, S.
    Tange, U. B.
    Soendergaard, S. B.
    Nielsen, D. L.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S173 - S173
12345